Simplovir 1 gm/vial (IV Infusion)
1 gm vial: ৳ 1,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Acyclovir injection |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of acute clinical manifestations of Herpes simplex virus in immunocompromised patients
- Treatment of severe primary or non-primary genital herpes in immune competent patients
- Treatment of Varicella zoster virus infection in immunocompromised patients
- Treatment of Herpes zoster (shingles) in immune competent patients with severe acute local or systemic manifestations
- Treatment of Herpes simplex encephalitis
Pharmacology
- Interferes with DNA synthesis of Herpes simplex virus and Varicella zoster virus
- Inhibits viral replication
- Dependence on intracellular conversion of the drug to Acyclovir Triphosphate
Dosage
- 5 mg/kg every 8 hours for Herpes simplex infection in normal or immunocompromised immune status
- 5 mg/kg every 8 hours for very severe Herpes zoster infection (shingles) in normal immune status
- 10 mg/kg every 8 hours for Varicella zoster infection in immunocompromised immune status
- 10 mg/kg every 8 hours for Herpes simplex encephalitis in normal or immunocompromised immune status
Administration
- Recommended duration of administration: 5-7 days for most infections, at least 10 days for Herpes simplex encephalitis
- Should be administered by slow intravenous infusion over a one-hour period
Interaction
- Co-administration of probenecid with Simplovir increases mean Simplovir half-life
- Urinary excretion and renal clearance reduced with co-administration of probenecid
- Significant increase in plasma levels of Simplovir in patients over 60 years of age with concurrent use of diuretics
Contraindications
- Contraindicated in patients hypersensitive to Acyclovir or Valacyclovir
Side Effects
- Lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma
- Phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes
- Increases in blood urea and creatinine
- Local inflammatory reactions if infused into extracellular tissues
Pregnancy & Lactation
- Pregnancy category B
- Not well studied in pregnant women
- Should only be administered to nursing mothers if benefits to mother outweigh potential risks to the baby
Precautions & Warnings
- Intended for intravenous infusion only
- Reconstituted IV infusion with pH of approximately 11.0 should not be administered by mouth
- Must be given over a period of at least one hour to avoid renal tubular damage
- Concomitant use of other nephrotoxic drugs, pre-existing renal disease, and dehydration increase risk of renal impairment
Use in Special Populations
- Pediatric use: Dose calculation based on body surface area
- Geriatric use: Special attention to dosage reduction due to low creatinine clearance
- In patients with renal impairment: Dosage modification based on creatinine clearance
Overdose Effects
- Elevations of serum creatinine and blood urea nitrogen
- Renal failure
- Neurological effects - confusion, hallucinations, agitation, seizures, and coma
- Adequate hydration essential to reduce possibility of crystal formation in the urine
Therapeutic Class
- Herpes simplex & Varicella-zoster virus infections
Duration of Treatment
- Recommended duration: 5-7 days for most infections, at least 10 days for Herpes simplex encephalitis
Reconstitution
- 250 mg vial reconstituted with 10 ml Water for Injection or Sodium Chloride Intravenous Infusion (0.9% w/v)
- 500 mg vial reconstituted with 10 ml Water for Injection or Sodium Chloride Intravenous Infusion (0.9% w/v)
Storage Conditions
- Store at 15°C to 25°C
- Protected from light and moisture
- Keep out of the reach of children